| Name | Title | Contact Details |
|---|
We bring the hospital to you! We deliver advanced medical care to where and when patients and their families want and need it. The Medically Home Program gives you more care over a longer period of time. We know getting well from a hospital-level illness or surgical procedure takes weeks, not days. With the Medically Home Program, you get the time you need - at home - with a single care team available to you the entire time. One of the secrets to getting better is being involved in – and understanding – your own care. The more time you and your family spend with our clinical care team, the more tools you will have to be get better. We know it can be hard for you to deal with medication, nutrition, stress and other health issues. The relationship we build during our time together will help us support your goal of getting better. Having the time to get to know you and your family is a big part of how we deliver care, because you really matter.
Barnes-Butler Inc is a Topeka, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Helping all patients feel known and heard when they need it most. Docent Health`s mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.
Osstem is a Fairless Hills, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.